Aclaris Therapeutics News and Activities

Aclaris Therapeutics is a company listed under the stock ticker ACRS (US).

View the org chart displaying its 19 main executives

Most searched biographies at Aclaris Therapeutics

• Neal Walker, Chief Executive Officer and Chairman of the Board
• Andrew Schiff, Director
• Maxine Gowen, Director

Create your alert
to follow the executive moves at Aclaris Therapeutics.

Aclaris Therapeutics has 1,913 competitors including Sanofi (France), Eli Lilly (United States (USA)) and Moderna (United States (USA)).

Popular M&A news in Pharmaceuticals

• Laboratoire Servier has announced the acquisition of Edgewise Therapeutics  (posted on June 4 2026).
• Contraline has just announced a $93 Million fundraising (posted on June 3 2026).
• Hims & Hers has acquired Eucalyptus (posted on June 2 2026).

Popular contacts in Pharmaceuticals

• Joaquin Duato - Chief Executive Officer and Chairman of the Board at Johnson & Johnson
• Robert Ford - Chief Executive Officer and Chairman of the Board at Abbott
• Jonathan Leff - Director at Larimar Therapeutics

Learn more about the Pharmaceuticals industry

Press releases by Aclaris Therapeutics

• Aclaris Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference | Aclaris Therapeutics, Inc.
• Aclaris Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate and Clinical Update | Aclaris Therapeutics, Inc.
• Aclaris Therapeutics to Participate in the 2026 Bank of America Healthcare Conference | Aclaris Therapeutics, Inc.
• Aclaris Therapeutics Announces Positive Full Top Line First-in-Human Results from Phase 1a Healthy Volunteer Clinical Trial of ATI-052, a Novel Potential First-in-Class Anti-TSLP/IL-4Rα Bispecific Antibody, and Announces Lichen Planus as Lead Indication f
• Aclaris Therapeutics to Provide Clinical Update on Key Biologic and Oral Inhibitor Programs on April 28, 2026 | Aclaris Therapeutics, Inc.
• Aclaris Therapeutics to Participate in the H.C. Wainwright 4th Annual Inflammatory Skin Disease Virtual Conference | Aclaris Therapeutics, Inc.
• Results Presented at 2026 American Academy of Dermatology (AAD) Annual Meeting Provide Additional Support for the Therapeutic Potential of ATI-2138 | Aclaris Therapeutics, Inc.
• Aclaris Therapeutics Announces Poster on Results from Phase 2a Trial of ATI-2138 at the 2026 American Academy of Dermatology (AAD) Annual Meeting | Aclaris Therapeutics, Inc.
• Aclaris Therapeutics Completes Enrollment in Phase 2 Trial of Bosakitug (ATI-045) in Atopic Dermatitis | Aclaris Therapeutics, Inc.
• Aclaris Therapeutics to Participate in the Leerink Partners 2026 Global Healthcare Conference | Aclaris Therapeutics, Inc.
• View more press releases Close

Social media about Aclaris Therapeutics

• Aclaris Therapeutics on Wikipedia, Google News & Yahoo Finance
• Aclaris Therapeutics on LinkedIn, X (Twitter) & YouTube